(Total Views: 236)
Posted On: 10/12/2023 5:05:38 PM
Post# of 50
NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has entered into a definitive agreement for the issuance and sale shares of its common stock. Specifically, the agreement calls for the issue and sale of 2,424,243 shares of Class A common stock, or common stock equivalents, for $1.65 per share in a registered direct offering. The announcement also noted that a concurrent private placement calling for Longeveron to issue and sell unregistered Series A warrants to purchase up to 2,424,243 shares of its common stock and unregistered Series B warrants to purchase up to 2,424,243 shares. The company anticipates the offering will close on or about Oct. 13, 2023, and will be subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has entered into a definitive agreement for the issuance and sale shares of its common stock. Specifically, the agreement calls for the issue and sale of 2,424,243 shares of Class A common stock, or common stock equivalents, for $1.65 per share in a registered direct offering. The announcement also noted that a concurrent private placement calling for Longeveron to issue and sell unregistered Series A warrants to purchase up to 2,424,243 shares of its common stock and unregistered Series B warrants to purchase up to 2,424,243 shares. The company anticipates the offering will close on or about Oct. 13, 2023, and will be subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
